The company stated that the FDA noted at least one additional adequate and well controlled study to demonstrate a positive ...

The nation's top vaccine regulator is stepping down — and he's not going quietly. Dr. Peter Marks, Director of the FDA’s ...

Aldeyra Therapeutics shares fell 73% to $1.42 in the regular session after it reported a Food and Drug Administration complete response letter for reproxalap for treatment of dry eye disease.